Files

Download

Download Full Text (523 KB)

Description

Introduction

In the United States, 34.2 million people are currently diagnosed with diabetes mellitus, which accounts for 10.5% of the total population.1 Type 2 diabetes mellitus (T2DM) holds 94.2% of all diabetes diagnoses. The American Association of Diabetes estimates approximately $327 billion annually and is broken up as follows:1

Publication Date

8-17-2023

Keywords

tirzepatide, GLP-1 receptor agonists, type-2 diabetes

Disciplines

Medicine and Health Sciences | Nephrology

Comments

Capstone presentations were completed in partial fulfillment of the Master of Science degree in Physician Assistant Studies at Thomas Jefferson University.

Document Type

Presentation

The Effectiveness of Tirzepatide (GIP/GLP-1 Receptor co-Agonist) vs GLP-1 Receptor Agonists on Lowering A1C in Adults with Type 2 Diabetes Mellitus

Included in

Nephrology Commons

Share

COinS